Skip to content

Compatibility of a low-FODMAP wheat bread compared to a regular wheat bread in persons suffering from irritable bowel syndrome: a randomized, controlled, double-blind crossover trial.

Compatibility of a low-FODMAP wheat bread compared to a regular wheat bread in persons suffering from irritable bowel syndrome: a randomized, controlled, double-blind crossover trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00013534
Enrollment
98
Registered
2017-12-15
Start date
2017-04-05
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K58

Interventions

Group 1: one-week gluten-free run-in period, first one-week bread phase (low-FODMAP wheatbread, 130 g daily), one-week wash-out Phase, second one-week bread phase (regular wheatbread, 130 g daily) Gro

Sponsors

Institut für Ernährungsmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Sufficient knowledge of the German language to understand the study documents and the information materials for implementation of the gluten-free diet • Irritable bowel syndrome diagnosis according to the Rome-III-criteria or RDS-like symptoms excluding other intestinal diseases

Exclusion criteria

Exclusion criteria: • Pregnancy, person in lactation • Diagnosis of other functional bowel diseases such as celiac disease, wheat allergy or inflammatory bowel disease • Alcohol addiction • Intake of medicines that affect the gastrointestinal tract, e.g. Antidiarrheals and proton pump inhibitors • Intake of antibiotics and/or probiotics during the last three months

Design outcomes

Primary

MeasureTime frame
At the end of each bread phase, changes in the irritable bowel syndrome (IBS)-severity during the FODMAP-reduced wheat phase compared to the regular wheat phase are determined using the IBS-Severity Scoring System (IBS-SSS) via a visual analogue scale (VAS).

Secondary

MeasureTime frame
At the beginning and at the end of the 1st, 2nd, 3rd and 4th week, changes in severity of intestinal and extraintestinal symptoms are analyzed individually and overall using VAS. At the same time points, quality of life using the EQ-5D-5L questionnaire are determined as well as the microbiome by stool sample analysis.

Countries

Germany

Contacts

Public ContactKatharina Schlumm

Institut für Ernährungsmedizin

brot-studie@uksh.de015150617180

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026